Subscribe free

HPB & Spleen ·

Combination therapy significantly enhances outcomes in advanced hepatocellular carcinoma

The integration of transarterial chemoembolization (TACE) with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) notably improves the objective response rate (RR = 1.81) and disease control rate (RR = 1.32) compared to TKIs and ICIs alone. Additionally, overall survival and progression-free survival are significantly prolonged, with hazard ratios of 0.55 and 0.73, respectively. While higher rates of pain and nausea/vomiting were observed, the therapy maintains an acceptable safety profile overall.

Comparative Study by Tian H and Wan C in World J Surg Oncol

© 2025. The Author(s).

read the whole article in World J Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

Br J Surg5 Nov 2026

Rectal cancer and liver spread: similar outcomes

Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.

All papers in HPB & Spleen →